Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
Crismon
M Lynn
ML
DeLeon
Anthony
A
Miller
Alexander L
AL
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D000068180:Aripiprazole; D018491:Dopamine Agonists / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole